Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1917-1922

  Masago, Katsuhiro ^a   Fujita, Shiro ^b   Kim, Yung Haku ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Nagai, Hiroki ^a   Irisa, Kaoru ^a   Ichikawa, Masataka ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTINEOPLASTIC AGENT; CYTOSINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GUANINE; PLATINUM COMPLEX; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SMOKING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349585443     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01253.x     Document Type: Article

References (31)

1. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-5.
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-5.
3. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-8.
4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-9.
5. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-12.
6. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996, 93:1493-5.
7. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999, 5:1359-64.
8. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18-32.
9. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005, 23:193-200.
10. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998, 18:1251-4.
11. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 1995, 55:5296-301.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-4.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-34.
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-50.
15. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003, 63:812-6.
16. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000, 12:1232-5.
17. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000, 37:443-8.
18. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002, 13:260-4.
19. Zhai R, Liu G, Zhou W, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 2008, 14:612-7.
20. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:856-62.
21. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 2005, 41:497-502.
22. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 2003, 62:374-7.
23. Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 2006, 15:1148-52.
24. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 2008, 35:17-22.
25. Summers AM, Coupes BM, Brennan MF, Ralph SA, Short CD, Brenchley PE. VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant 2005, 20:2427-32.
26. Balasubramanian SP, Brown NJ, Reed MW. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002, 87:1057-65.
27. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:870-8.
28. Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006, 8:R22.
29. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004, 46:293-8.
30. Unal ZN, Unal M, Bagdatoglu OT, Polat G, Atik U. Genetic polymorphism of VEGF-1154 (A/G) in laryngeal squamous cell carcinoma. Arch Med Res 2008, 39:209-11.
31. Chakra M, Pujol JL, Lamy PJ, et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008, 3:1119-26.